These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25877323)

  • 21. Diagnosis and treatment of lung cancer: summary of updated NICE guidance.
    Baldwin DR; White B; Schmidt-Hansen M; Champion AR; Melder AM;
    BMJ; 2011 Apr; 342():d2110. PubMed ID: 21525094
    [No Abstract]   [Full Text] [Related]  

  • 22. Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison.
    Christensen NL; Jekunen A; Heinonen S; Dalton SO; Rasmussen TR
    Acta Oncol; 2017 Jul; 56(7):943-948. PubMed ID: 28418710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off the mark: Current lung cancer screening guidelines miss those most at risk.
    Printz C
    Cancer; 2015 Aug; 121(15):2477-8. PubMed ID: 26198788
    [No Abstract]   [Full Text] [Related]  

  • 24. Delay between the initial symptoms, the diagnosis and the onset of specific treatment in elderly patients with lung cancer.
    Giroux Leprieur E; Labrune S; Giraud V; Gendry T; Cobarzan D; Chinet T
    Clin Lung Cancer; 2012 Sep; 13(5):363-8. PubMed ID: 22264658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2019 edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):257-287. PubMed ID: 32375445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for guidelines: we've come a long way.
    Clancy CM; Slutsky JR
    Chest; 2007 Sep; 132(3):746-7. PubMed ID: 17873187
    [No Abstract]   [Full Text] [Related]  

  • 27. Saudi Lung Cancer Guidelines Supplement 2012. Introduction from the Guest Editor.
    Hirsh V
    J Infect Public Health; 2012 Dec; 5 Suppl 1():S2-3. PubMed ID: 23244182
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical Guidelines for the Management of Lung Cancer and evaluation from clinical practice].
    Morikawa T
    Nihon Geka Gakkai Zasshi; 2007 Sep; 108(5):237-41. PubMed ID: 17907451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should family physicians routinely screen for lung cancer in high-risk populations? No: The USPSTF's recommendation for lung cancer screening is overreaching.
    Seehusen DA
    Am Fam Physician; 2014 Jul; 90(2):73D-4D. PubMed ID: 25077590
    [No Abstract]   [Full Text] [Related]  

  • 30. Parenchymal asbestosis can lead to lung cancer within a short time frame: more frequent follow-up surveillance is needed than currently recommended.
    Murlidhar V
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25878233
    [No Abstract]   [Full Text] [Related]  

  • 31. [China Medical University Successfully Held Top-level Academic Conference of "Lung Cancer Forum - 2018 Shenyang" and Signed IASLC-CLCC Collaboration Agreements on Lung Cancer Study and Clinical Diagnosis and Treatment].
    Zhang J
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):652-654. PubMed ID: 30172275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New guidelines for LAM diagnosis and treatment.
    Lobo P
    Lancet Respir Med; 2016 Nov; 4(11):862. PubMed ID: 27742353
    [No Abstract]   [Full Text] [Related]  

  • 33. Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd Edition).
    McCrory DC; Lewis SZ; Heitzer J; Colice G; Alberts WM;
    Chest; 2007 Sep; 132(3 Suppl):23S-28S. PubMed ID: 17873158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [III. Method and current problem of follow up and future possibility of clinical trials for lung cancer-based on practice guideline].
    Shiono S
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1201-4. PubMed ID: 22984697
    [No Abstract]   [Full Text] [Related]  

  • 35. [Commentary to the diagnostic and therapeutic recommendations of Polish Lung Cancer Group (see page 88)].
    Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):1. PubMed ID: 17541905
    [No Abstract]   [Full Text] [Related]  

  • 36. [Development Status and Thinking of the "Integrated Diagnosis and Treatment, Full-course Management" Model of Lung Cancer- Based on the Experience of the Lung Cancer MDT Team of Sichuan Cancer Hospital].
    Xiang R; Li Q
    Zhongguo Fei Ai Za Zhi; 2020 Apr; 23(4):211-215. PubMed ID: 32316710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Concept of quality assurance in the management of lung carcinoma].
    Blankenburg T; Flentje M; Friedel G; Huber RM; Tesch H
    Onkologie; 2006 Sep; 29 Suppl 2():20-4. PubMed ID: 16974124
    [No Abstract]   [Full Text] [Related]  

  • 38. Prologue.
    Duque Medina JL
    Arch Bronconeumol; 2016 May; 52 Suppl 1():1. PubMed ID: 27389766
    [No Abstract]   [Full Text] [Related]  

  • 39. KRAS mutation spectrum notably diverges between non-small cell lung and colorectal carcinomas.
    Compagnone M; Chetaille B; Olschwang S
    J Thorac Oncol; 2012 Apr; 7(4):773-4; author reply 774. PubMed ID: 22425934
    [No Abstract]   [Full Text] [Related]  

  • 40. 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy.
    Gridelli C; Rossi A; Maione P
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S248-57. PubMed ID: 21943982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.